For the Inventor, By the Inventor

Enter assignee name

Hellerup, Denmark

Ascendis Pharma Growth Disorders A/s

USPTO Granted Patents = 12

CIPO Patents = 12

EPO Patents = 3

Trademarks = 2

Forward Citations = 51

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Ulrich Hersel (11 out of 40 patents)

Harald Rau (10 out of 56 patents)

Felix Cleemann (9 out of 23 patents)

4. Kennett Sprogøe (8 out of 28 patents)

5. Caroline Elisabeth Rasmussen (5 out of 5 patents)

6. Thomas Wegge (2 out of 38 patents)

7. Frank Faltinger (1 out of 1 patent)

8. Ana Bernhard (1 out of 1 patent)

9. Felix Cleenmann (1 out of 1 patent)

10. Lars Holten-Andersen (1 out of 6 patents)

11. Vibeke Miller Breinholt (1 out of 1 patent)

12. Charlotte Pinholt (1 out of 1 patent)

13. Stefan Heinig (1 out of 1 patent)

14. Anja R H Skands (1 out of 2 patents)

15. Dirk Vetter (21 patents)

12 patents: Sort by Forward Citations

1. 12377133 - Dry pharmaceutical formulations of CNP conjugates (2025-08-05),

2. 12239689 - Controlled-release CNP agonists with low initial NPR-B activity (2025-03-04),

3. 12156917 - CNP prodrugs with carrier attachment at the ring moiety (2024-12-03),

4. 12083182 - Controlled-release CNP agonists with increased NEP stability (2024-09-10),

5. 11564974 - Combination therapy with controlled-release CNP agonists (2023-01-31),

6. 11413351 - CNP prodrugs with carrier attachment at the ring moiety (2022-08-16),

7. 11389511 - Controlled-release CNP agonists with reduced side-effects (2022-07-19),

8. 11389510 - Controlled-release CNP agonists with low initial NPR-B activity (2022-07-19),

9. 11311604 - Controlled-release CNP agonists with low NPR-C binding (2022-04-26),

10. 11224661 - Controlled-release CNP agonists with increased NEP stability (2022-01-18),

11. 11154593 - CNP prodrugs with large carrier moieties (2021-10-26),

12. 10835578 - CNP prodrugs with large carrier moieties (2020-11-17),

Ascendis Pharma Growth Disorders A/S is a biopharmaceutical company focused on developing transformative therapies for rare endocrine diseases. Their innovative pipeline includes treatments for growth hormone deficiency and achondroplasia, utilizing their proprietary TransCon technology platform to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

12 Patents

#3 in Hellerup

#224 in Denmark

#46,665 in the World

Hellerup, Denmark

Ascendis Pharma Growth Disorders A/s

Forward Citations = 51

24 inventors:

Ulrich Hersel (11 out of 40 patents)

Harald Rau (10 out of 56 patents)

Felix Cleemann (9 out of 23 patents)

4. Kennett Sprogøe (8 out of 28 patents)

5. Caroline Elisabeth Rasmussen (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…